IMRT planning studies for dose escalation to 80.5 Gy with locally advanced head and neck tumors - Preparations for dose specification for a new German multi-center study with DFG funding

被引：0
|
作者：
Schill, S. [1 ]
Pigorsch, S. [1 ]
机构：
[1] Tech Univ Munich, Klinikum Rechts Isar, Klin & Poliklin Strahlentherapie & Radiol Onkol, Munich, Germany
来源：
STRAHLENTHERAPIE UND ONKOLOGIE | 2009年 / 185卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：92 / 92
页数：1
相关论文
共 18 条
  • [1] Gradual Dose Escalation to 80.5 Gy with Head and Neck Cancer in the ESCALOX Study - IMRT Planning with SIB in 3 Steps
    Schill, S.
    Kampfer, S.
    Molls, M.
    Pigorsch, S.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2013, 189 : 98 - 99
  • [2] Sunitinib versus imatinib dose escalation after failure of imatinib standard dose in patients with advanced Gastrointestinal stromal tumors - a real-world multi-center study
    Huang, Shaoqing
    Liu, Xing
    Guo, Xiaodan
    Wu, Hui
    Lu, Huishan
    Pan, Zhizhong
    Cai, Shirong
    Wu, Xiaojun
    Zhang, Xinhua
    TRANSLATIONAL ONCOLOGY, 2023, 30
  • [3] Phase I, multi-center, dose-escalation and dose-expansion study of IMP7068, a WEE1 inhibitor, in patients with advanced solid tumors
    Lin, C-C.
    Grewal, J.
    Baranda, J. C.
    Schneider, R. E.
    Zhang, J.
    Bai, L-Y.
    Yeh, Y-M.
    Sommerhalder, D.
    Li, G.
    Shen, L.
    Hsu, H-C.
    Alese, O.
    Yin, R.
    Hsieh, C-Y.
    Cai, S. X.
    Tian, Y. E.
    Xia, H.
    Li, B.
    Zhang, M.
    Zhang, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S466 - S466
  • [4] Phase I, multi-center, open-label, dose-escalation study of pasireotide LAR (PAS) in patients with advanced neuroendocrine tumors (NET)
    Strosberg, Jonathan R.
    Chan, Jennifer A.
    Mita, Alain C.
    Kundu, Madan
    Valera, Sue-zette
    Unge, Peter
    Darstein, Christelle
    Hu, Mike
    Wolin, Edward M.
    Yao, James C.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] Phase I, Multi-center, Open-label, Dose-escalation Study of Pasireotide LAR (PAS) in Patients With Advanced Neuroendocrine Tumors (NET)
    Strosberg, Jonathan
    Chan, Jennifer
    Mita, Alain
    Kundu, Madan
    Hermosillo, Karina
    Hu, Ke
    Wolin, Edward
    Yao, James
    PANCREAS, 2017, 46 (03) : 437 - 437
  • [6] CBP-1018, a bi-ligand-drug conjugate treated in patients with advanced solid tumors: A phase I, multi-center, openlabel, dose-escalation and dose expansion study
    Li, K.
    Wu, J.
    Ye, S.
    Liu, Y.
    Huang, H.
    Fan, F.
    Lai, Y.
    Zhuang, S.
    Zhou, L.
    Huang, R.
    Teng, Y.
    Chai, X.
    Zhang, J.
    Shi, Y.
    Huang, H.
    ANNALS OF ONCOLOGY, 2023, 34 : S991 - S991
  • [7] Safety and Efficacy of Pasireotide LAR (PAS) in Patients with Advanced Neuroendocrine Tumors (NET): Findings of a Phase I, Multi-Center, Open-Label, Dose-Escalation Study
    Yao, J.
    Chan, J.
    Mita, A.
    Kundu, M.
    Valera, S. Z.
    Unge, P.
    Strosberg, J.
    Wolin, E.
    NEUROENDOCRINOLOGY, 2016, 103 : 76 - 76
  • [8] A phase 1, multi-center, open-label, dose-escalation and dose expansion study of CBP-1018, a bi-ligand-drug conjugate, in patients with heavily treated advanced solid tumors
    Li, Kaiwen
    Wu, Junyan
    Ye, Suiwen
    Liu, Yanqiong
    Huang, Hao
    Fan, Fan
    Lai, Yiming
    Zhuang, Suili
    Zhou, Liyan
    Huang, Robert
    Teng, Yan
    Chai, Xiaoyan
    Shi, Yehui
    Huang, Hai
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] A phase I/II dose escalation study of the CDK4/6 inhibitor, palbociclib in combination with cetuximab and intensity modulated radiation therapy (IMRT) for locally advanced squamous cell carcinoma of the head and neck (SCCHN)
    Ngamphaiboon, N.
    Lukerak, S.
    Jiarpinitnun, C.
    Jinawath, A.
    Jinawath, N.
    Juengsamarn, J.
    Arsa, L.
    Konmun, J.
    Kongsuphon, N.
    Sankaseam, N.
    Sirachainan, E.
    Witoonpanich, P.
    Kositwattanarerk, A.
    Pattaranutaporn, P.
    ANNALS OF ONCOLOGY, 2018, 29
  • [10] MRL-02: ADC-based, adaptive MR-guided SBRT Boost in Patients with locally advanced Head and Neck Tumors: Protocol Presentation of a non-randomized Phase I Dose Escalation Study and initial Planning Study
    Boeke, S.
    Habrich, J.
    Nachbar, M.
    Butzer, S.
    Boldt, J.
    Moennich, D.
    Schick, F.
    Nikolaou, K.
    Wegener, D.
    Gani, C.
    Thorwarth, D.
    Zips, D.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2022, 198 (SUPPL 1) : S92 - S93
12